Peptide dosing library

Browse peptide dose references, source-linked schedules and downloadable charts. Explore the science with myPeptides.

5-Amino-1MQ

Preclinical metabolic research · SubQ mouse studies · Human dose unresolved

An NNMT inhibitor studied in mice. Neither a human oral nor a human SubQ regimen is established by the cited research.

Abaloparatide

Adults · Osteoporosis at high fracture risk · US Tymlos

Abaloparatide is a PTH-related peptide analogue. This reference covers the US Tymlos osteoporosis label. Adults · Osteoporosis at high fracture risk · US Tymlos.

Ac-SDKP

Six healthy volunteers · Single SubQ exposure · Ezan 1994

Ac-SDKP is a thymosin beta-4-derived tetrapeptide. This card records a small human pharmacokinetic experiment. Six healthy volunteers · Single SubQ exposure · Ezan 1994.

Adamax

Identity / data gap · No established human dosing schedule

Adamax is a marketed Semax-related research name. A reproducible human dose has not been established. Identity / data gap · No established human dosing schedule.

Adipotide

Nonhuman-primate research · SubQ · Renal safety signal

A preclinical adipose-vasculature targeting compound. The primate study reported renal effects and does not establish a human SubQ regimen.

AHK-Cu

Cells / follicles · No established human dosing schedule

AHK-Cu is a copper peptide studied in cultured hair follicles and cells. Those experiments do not define a human hair-growth dose. Cells / follicles · No established human dosing schedule.

AICAR

Adults undergoing CABG · Intravenous infusion · RED-CABG, 2012

Human acadesine research used monitored IV infusion in cardiac surgery. It does not establish a SubQ metabolic or endurance protocol.

AOD-9604

SubQ evidence gap · Human oral/IV research reviewed by FDA, 2024

An evidence card for SubQ claims: FDA’s review found no human SubQ data and insufficient evidence for obesity treatment.

Ara-290

Sarcoidosis-associated small-fibre loss · 28-day phase 2b trial

Ara-290 (cibinetide) is an investigational peptide. These are separate dose arms from a sarcoidosis trial. Sarcoidosis-associated small-fibre loss · 28-day phase 2b trial.

BPC-157

Predominantly animal · No established human dosing schedule

BPC-157 is an investigational peptide with mostly animal evidence. The reviewed sources do not establish a routine human SubQ dose. Predominantly animal · No established human dosing schedule.

Brenipatide

Adults · Phase 1 NCT06606106 · Sponsor poster, September 2026

Brenipatide is an investigational GIP/GLP-1 agonist. The listed amounts are target levels from a phase 1 poster. Adults · Phase 1 NCT06606106 · Sponsor poster, September 2026.

Bronchogen

Animal airway models · No established human dosing schedule

Bronchogen is the AEDL tetrapeptide investigated in animal airway models. A human respiratory dosing schedule is not established. Animal airway models · No established human dosing schedule.